• 19Sep

    Accomplished Seattle Genetics CEO, co-founder, and board chairman, Clay Siegall, Ph.D., was appointed to the board of Mirna Therapeutics in January 2013. Siegall’s appointment allowed him to serve the private biotechnology company as its outside director.

    Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.

    Mirna Therapeutics is based in Austin, Texas. The company was founded in 2007 and currently focuses on developing microRNA in therapeutics. The company’s main focus is in cancer research, a field that Siegall has a wealth of knowledge in. Paul Lammers, the CEO of Mirna Therapeutics, expressed his excitement at the appointment and confirmation of Clay Siegall into their Board of Directors.

    Lammers said that he expected Siegall to be invaluable in guiding the company through its research and advancements in the development of microRNA therapeutics. He acknowledged that the hiring decision was an excellent one.

    Clay Siegall, Ph.D.

    Clay Siegall helped to co-find and establish Seattle Genetics. Today, he serves as company CEO and the Chairman of its Board of Directors. Under the direction and management of Siegall, the company successfully created working antibody-based therapies that are useful for cancer patients who are not adequately taken care of – in terms of their medical needs. Additionally, Siegall holds 15 patents and is a successfully published author with over 70 published works.

    Siegall attended University of Maryland and graduated four years later with a Bachelor of Science Degree in Zoology. He later enrolled at George Washington University for his Ph.D. in Genetics. After graduating, he secured employment at the National Cancer Institute, National Institutes of Health. He later worked at Bristol-Myers Squibb Pharmaceutical Research Institute. He left the company to start Seattle Genetics back in 1998.

    Seattle Genetics

    Today, Seattle Genetics is one of the country’s leading biotechnology companies that specializes in the development of preclinical and clinical products. Since its inception, the company has commercialized innovative and effective antibody-drug conjugate (ADC) that is useful for cancer treatment.

    The company has curved out a name for itself in the industry as a rigorous research facility dedicated to the development and improvement of scientific innovations and useful drug development practices relevant to medicine. The company’s headquarters are located in Bothell Washington. It is traded on the Nasdaq Stock Market.

Leave a Reply

Your email address will not be published. Required fields are marked *



Single Links